Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients

Clinical Breast Cancer

Volumn 11, Issue 6, 2011, Pages 369-375

  Ibrahim, Toni ^a   Sacanna, Emanuele ^a   Gaudio, Michele ^b   Mercatali, Laura ^a   Scarpi, Emanuela ^a   Zoli, Wainer ^a   Serra, Patrizia ^a   Ricci, Rossana ^a   Serra, Luigi ^b   Kang, Yibin ^c   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c PRINCETON UNIVERSITY   (United States)

Author keywords

Bone metastases; Breast cancer; CXCR4; OPG; RANK RANKL

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; OSTEOCLAST DIFFERENTIATION FACTOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER RELAPSE; CLINICAL ARTICLE; FEMALE; HUMAN; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR CELL; VISCERAL METASTASIS;

EID: 82255191389     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.05.001     Document Type: Article

References (44)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 2006 6243s 6249s (Pubitemid 44703797)
3. S. Fili, M. Karalaki, and B. Schaller Therapeutic implications of osteoprotegerin Cancer Cell Int 9 2009 26
4. S. Fili, M. Karalaki, and B. Schaller Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors Cancer Lett 283 2009 10 19
5. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593 (Pubitemid 37328925)
6. W.C. Dougall RANKL signaling in bone physiology and cancer Curr Opin Support Palliat Care 1 2007 317 322
7. D.H. Jones, T. Nakashima, and O.H. Sanchez Regulation of cancer cell migration and bone metastasis by RANKL Nature 440 2006 692 696
8. J.M. Blair, H. Zhou, and M.J. Seibel Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis Nat Clin Pract Oncol 3 2006 41 49 (Pubitemid 43108833)
9. G. Chen, K. Sircar, and A. Aprikian Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation Cancer 107 2006 289 298 (Pubitemid 44036558)
10. J.M. Brown, J. Zhang, and E.T. Keller OPG, RANKl, and RANK in cancer metastasis: expression and regulation Cancer Treat Res 118 2004 149 172
11. F.C. Perez-Martinez, V. Alonso, and J.L. Sarasa Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma Histol Histopathol 23 2008 709 715 (Pubitemid 351552356)
12. A. Dar, O. Kollet, and T. Lapidot Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice Exp Hematol 34 2006 967 975 (Pubitemid 44080383)
13. S. Gelmini, M. Mangoni, and M. Serio The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis J Endocrinol Invest 31 2008 809 819
14. R.E. Coleman, H.C. Thorpe, and D. Cameron Adjuvant treatment with Zoledronic Acid in stage II/III breast cancer The Azure Trial (BIG 01/04) San Antonio Breast Cancer Symposium 2010 S4 S5
15. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 41 2002 154 161
16. O. Salvucci, A. Bouchard, and A. Baccarelli The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study Breast Cancer Res Treat 97 2006 275 283 (Pubitemid 43945757)
17. L. Hao, C. Zhang, and Y. Qiu Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer Cancer Lett 253 2007 34 42 (Pubitemid 46881198)
18. N. Cabioglu, A. Sahin, and M. Doucet Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow Clin Exp Metastasis 22 2005 39 46 (Pubitemid 41185860)
19. N. Cabioglu, A.A. Sahin, and P. Morandi Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications Ann Oncol 20 2009 1013 1019
20. I. Holen, S.S. Cross, and H.L. Neville-Webbe Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - a role in tumour cell survival? Breast Cancer Res Treat 92 2005 207 215 (Pubitemid 41279631)
21. M. Trinkaus, W.S. Ooi, and E. Amir Examination of the mechanisms of osteolysis in patients with metastatic breast cancer Oncol Rep 21 2009 1153 1159
22. C. Van Poznak, S.S. Cross, and M. Saggese Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours J Clin Pathol 59 2006 56 63 (Pubitemid 43076239)
23. S.S. Cross, R.F. Harrison, and S.P. Balasubramanian Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables J Clin Pathol 59 2006 716 720 (Pubitemid 44048780)
24. D. Santini, G. Perrone, and I. Roato Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases J Cell Physiol 226 2011 780 784
25. Sacanna E, Ibrahim T, Gaudio M, et al. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. Oncology (In press).
26. B.C. Schmid, M. Rudas, and G.A. Rezniczek CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia Breast Cancer Res Treat 84 2004 247 250 (Pubitemid 38445374)
27. M. Kato, J. Kitayama, and S. Kazama Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma Breast Cancer Res 5 2003 144 150
28. B. Furusato, A. Mohamed, and M. Uhlén CXCR4 and cancer Pathol Int 60 2010 497 505
29. H. Shim, S.K. Lau, and S. Devi Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha Biochem Biophys Res Commun 346 2006 252 258 (Pubitemid 43865990)
30. Y.C. Huang, Y.C. Hsiao, and Y.J. Chen Stromal cell-derived factor-1 enhances motility and integrin up-regulation through CXCR4, ERK and NF-kappaB-dependent pathway in human lung cancer cells Biochem Pharmacol 74 2007 1702 1712
31. H. Kang, G. Watkins, and A. Douglas-Jones The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer Breast 14 2005 360 367 (Pubitemid 41510192)
32. F. Andre, W. Xia, and R. Conforti CXCR4 expression in early breast cancer and risk of distant recurrence Oncologist 14 2009 1182 1188
33. S. Hassan, C. Ferrario, and U. Saragovi The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer Am J Pathol 175 2009 66 73
34. B.J. Frisch, R.L. Porter, and L.M. Calvi Hematopoietic niche and bone meet Curr Opin Support Palliat Care 2 2008 211 217
35. H. Libouban, M.F. Moreau, and M.F. Basle Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse Biochem Biophys Res Commun 316 2004 859 866 (Pubitemid 38368032)
36. G. van der Pluijm, I. Que, and B. Sijmons Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo Cancer Res 65 2005 7682 7690 (Pubitemid 41297242)
37. M. Gnant, B. Nkineritsch, and H. Stoeger Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer J Clin Oncol 28 suppl 15 2010 abstract 533
38. I.J. Diel, A. Jaschke, and E.F. Solomayer Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up Ann Oncol 19 2008 2007 2011
39. R.E. Coleman The role of bisphosphonates in breast cancer Breast 13 suppl 1 2004 S19 S28 (Pubitemid 39654740)
40. A.T. Stopeck, A. Lipton, and J.J. Body Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139
41. R.N. Pearse New strategies for the treatment of metastatic bone disease Clin Breast Cancer 8 suppl 1 2007 S35 S45 (Pubitemid 351204452)
42. B. Wei, J. Wang, and P. Bourne Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas Hum Pathol 39 2008 1809 1815
43. Y.H. Park, S. Lee, and E.Y. Cho Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status Cancer Chemother Pharmacol 66 2010 507 516
44. S. Becker, G. Becker-Pergola, and T. Fehm Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients Anticancer Res 25 2005 2171 2175 (Pubitemid 40904619)